Shares of RingCentral Inc (NYSE:RNG) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results and raised its FY26 guidance above estimates.

RingCentral reported quarterly earnings of $1.33 per share which beat the analyst consensus estimate of $1.28 per share. The company reported quarterly sales of $676.043 million which beat the analyst consensus estimate of $667.035 million.

RingCentral shares jumped 15% to $91.33 in pre-market trading

Here are some other stocks moving in pre-market trading.

Gainers

• 22nd Century Group Inc (NASDAQ:XXII) gained 64.6% to $0.36 in pre-market trading. 22nd Century Group shares dipped over 20% on Thursday after the company reported a quarter-over-quarter increase of its preliminary Q3 net revenue results.
• Lakewood-amedex Biotherapeutics Inc (NASDAQ:LABT) gained 56.8% to $0.77 in pre-market trading. The company recently announced the presentation of preclinical Nu-3 data, with the next catalyst remaining Phase 2a topline results in Q1 2027.
• Hub Cyber Security Ltd (NASDAQ:HUBC) gained 47.2% to $0.30 in pre-market trading after dipping 33% on Thursday.
• Lucid Diagnostics Inc (NASDAQ:LUCD) jumped 26.6% to $0.42 in pre-market trading after the company announced that begun receiving Medicare reimbursement payments for its EsoGuard Esophageal DNA Test
• Tantech Holdings Ltd (NASDAQ:TANH) gained 26.1% to $31.30 in pre-market trading after jumping 87% on Thursday.
• Aardvark Therapeutics Inc (NASDAQ:AARD) rose 20.7% to $4.77 in pre-market trading after the clinical-stage biopharmaceutical said the Food and Drug Administration lifted the clinical hold on its Prader-Willi Syndrome (PWS) drug candidate.
• Hyperscale Data Inc (NYSE:GPUS) gained 17.8% to $0.15 in pre-market trading after the AI data center company suspended its at-the-market (ATM) stock offering.
• PAVmed Inc (NASDAQ:PAVM) rose 16.9% to $2.40 in pre-market trading as the company announced that it has begun receiving payments from Medicare for its EsoGuard Esophageal DNA Test.
• Maxlinear Inc (NASDAQ:MXL) gained 10.1% to $71.86 in pre-market trading as the company reported upbeat earnings for the third quarter.

Losers

• Lunai Bioworks Inc (NASDAQ:LNAI) fell 36.2% to $0.30 in pre-market trading after the company announced receipt of Nasdaq determination and intention to voluntarily delist and deregister.
• BranchOut Food Inc. (NASDAQ:BOF) fell 14.4% to $1.73 in pre-market trading after announcing a proposed public offering.
• Pomdoctor Limited (NASDAQ:POM) fell 13.4% to $1.76 in pre-market trading after dipping 33% on Thursday.
• Darkiris Inc. (NASDAQ:DKI) fell 12.8% to $1.9599 in pre-market trading after gaining around 13% on Thursday.
• Enlivex Ltd. (NASDAQ:ENLV) fell 11.6% to $0.1760 in pre-market trading. Enlivex disclosed a 1-for-16 reverse share split to be effective Oct. 27.
• BayCom Corp (NASDAQ:BCML) tumbled 11.4% to $28.23 in pre-market trading after posting weak quarterly results.
• Eason Technology Limited (NYSE:DXF) fell 11.2% to $0.3019 in pre-market trading. Eason Technology announced that its subsidiary, Four Ele Industry, has been granted a patent for an industrial park smart grid dispatch system.
• High Roller Technologies, Inc. (NYSE:ROLR) fell 10.6% to $4.44 in pre-market trading. High Roller Technologies recently announced the commercial launch of its real-money prediction markets platform ROLR.
• Nyxoah SA (NASDAQ:NYXH) declined 10.4% to $0.7356 in pre-market trading. Nyxoah recently lowered its FY26 revenue guidance.
• Deckers Outdoor Corporation (NYSE:DECK) fell 9.1% to $77.50 in pre-market trading after the company reported mixed second-quarter financial results and cut its FY27 sales guidance below estimates.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.